Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.

Irwin DJ, Trojanowski JQ, Grossman M.

Front Aging Neurosci. 2013 Feb 21;5:6. doi: 10.3389/fnagi.2013.00006. eCollection 2013.

2.

Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.

Baldeiras I, Santana I, Leitão MJ, Ribeiro MH, Pascoal R, Duro D, Lemos R, Santiago B, Almeida MR, Oliveira CR.

J Neurol Sci. 2015 Nov 15;358(1-2):308-16. doi: 10.1016/j.jns.2015.09.022. Epub 2015 Sep 10.

PMID:
26388316
3.

Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.

Irwin DJ, Lleó A, Xie SX, McMillan CT, Wolk DA, Lee EB, Van Deerlin VM, Shaw LM, Trojanowski JQ, Grossman M.

Ann Neurol. 2017 Aug;82(2):247-258. doi: 10.1002/ana.24996. Epub 2017 Aug 19.

PMID:
28719018
4.

Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.

Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, Arai H, Furukawa K.

J Neurochem. 2016 Jan;136(2):258-61. doi: 10.1111/jnc.13399. Epub 2015 Nov 11.

5.

CSF biomarkers in frontotemporal lobar degeneration with known pathology.

Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S, Trojanowski J, Lee VM, Grossman M.

Neurology. 2008 May 6;70(19 Pt 2):1827-35. doi: 10.1212/01.wnl.0000311445.21321.fc.

6.

Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.

Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang LS, Van Deerlin V, Lee VM, Trojanowski JQ, Grossman M.

Arch Neurol. 2012 Aug;69(8):1018-25. doi: 10.1001/archneurol.2012.26.

7.

A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.

Lleó A, Irwin DJ, Illán-Gala I, McMillan CT, Wolk DA, Lee EB, Van Deerlin VM, Shaw LM, Trojanowski JQ, Grossman M.

JAMA Neurol. 2018 Jun 1;75(6):738-745. doi: 10.1001/jamaneurol.2018.0118.

PMID:
29554190
8.

Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration.

Goossens J, Bjerke M, Van Mossevelde S, Van den Bossche T, Goeman J, De Vil B, Sieben A, Martin JJ, Cras P, De Deyn PP, Van Broeckhoven C, van der Zee J, Engelborghs S.

Alzheimers Res Ther. 2018 Mar 20;10(1):31. doi: 10.1186/s13195-018-0364-0.

9.

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Acta Neuropathol. 2011 May;121(5):597-609. doi: 10.1007/s00401-011-0808-0. Epub 2011 Feb 11.

10.

Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia.

Borroni B, Benussi A, Archetti S, Galimberti D, Parnetti L, Nacmias B, Sorbi S, Scarpini E, Padovani A.

Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar;16(1-2):86-91. doi: 10.3109/21678421.2014.971812. Epub 2014 Oct 29.

PMID:
25352065
11.

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes.

Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE.

Alzheimers Dement (Amst). 2015 Dec 14;1(4):505-12. doi: 10.1016/j.dadm.2015.11.001. eCollection 2015 Dec.

12.

Can MRI screen for CSF biomarkers in neurodegenerative disease?

McMillan CT, Avants B, Irwin DJ, Toledo JB, Wolk DA, Van Deerlin VM, Shaw LM, Trojanoswki JQ, Grossman M.

Neurology. 2013 Jan 8;80(2):132-8. doi: 10.1212/WNL.0b013e31827b9147. Epub 2012 Dec 26.

13.

Novel CSF biomarkers for frontotemporal lobar degenerations.

Hu WT, Chen-Plotkin A, Grossman M, Arnold SE, Clark CM, Shaw LM, McCluskey L, Elman L, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Neurology. 2010 Dec 7;75(23):2079-86. doi: 10.1212/WNL.0b013e318200d78d. Epub 2010 Nov 3.

14.

Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update.

Oeckl P, Steinacker P, Feneberg E, Otto M.

J Neurochem. 2016 Aug;138 Suppl 1:184-92. doi: 10.1111/jnc.13669. Epub 2016 Jun 15. Review.

15.

Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives.

Oeckl P, Steinacker P, Feneberg E, Otto M.

Biochim Biophys Acta. 2015 Jul;1854(7):757-68. doi: 10.1016/j.bbapap.2014.12.010. Epub 2014 Dec 17. Review.

PMID:
25526887
16.

Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration.

Galimberti D, Scarpini E.

Int J Clin Exp Med. 2010 May 15;3(2):129-43.

17.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group.

J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.

PMID:
26401938
18.

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.

Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.

J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.

PMID:
25391385
19.

Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A, Winblad B, Schott JM, Blennow K, Eriksdotter M, Zetterberg H.

Brain. 2015 Sep;138(Pt 9):2716-31. doi: 10.1093/brain/awv181. Epub 2015 Jun 30.

PMID:
26133663
20.

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios.

Marelli C, Gutierrez LA, Menjot de Champfleur N, Charroud C, De Verbizier D, Touchon J, Douillet P, Berr C, Lehmann S, Gabelle A.

Alzheimers Dement (Amst). 2015 Jun 28;1(3):371-9. doi: 10.1016/j.dadm.2015.06.004. eCollection 2015 Sep.

Supplemental Content

Support Center